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stroke, it becomes imperative to recognize and treat the
underlying etiology for appropriate secondary prevention of
vascular events. Antiplatelet agents remain the mainstay of
therapy among such patients, including patients undergoing
PCI or carotid stenting and the ones managed medically for
prevention of future atherothrombotic events. As per consen-
sus guidelines, early revascularization and intensive anti-
platelet therapy have been proposed as key strategies to
minimize complications secondary to myocardial ischemia
and future recurrent events.1
For advent of a more effective treatment, apart from the
standard therapies with aspirin and clopidogrel, newer P2Y12
receptor antagonist antiplatelet agents have been discovered
and studied in major cardiology RCT's for efﬁcacy and safety.2
These include oral agents prasugrel,3–6 ticagleror,7,8 and
vorapaxar, as well as intravenous agents cangrelor and
elinogrel.9 However, the efﬁcacy of these agents has to be
balanced against bleeding complications, with intracranial
bleeding being a very serious event. Moreover, they may
increase the risk of traumatic hemorrhage, which may be
difﬁcult to control and disastrous, especially in the elderly.
In the current issue of this journal, Suryanarayna and
colleagues describe a case of nontraumatic subdural hemato-
ma (SDH) in a patient on treatment with dual antiplatelet
therapy with aspirin and ticagrelor following a PCI for unstable
angina. The patient presented with a recent onset headache
with no other focal neurological deﬁcits, and neuroimaging
with a brain CT revealed a small right-sided SDH. Luckily, for
the patient, the bleed did not expand and was managed
conservatively. However, the patient was shifted from
ticagleror to clopidogrel based on concerns of a recent stenting
procedure. The authors discuss the concerns of ICH with
special reference to the newer antiplatelet therapy.
Risk of intracranial bleed with antiplatelet agents has been
studied in various stroke and ACS trials as an important safety
endpoint (Table 1). With increasingly intensive antiplatelet
therapy, the risk of bleeding complications is likely to rise. In
the randomized blinded trial of clopidogrel versus aspirin in
patients at risk of ischemic events, among a total of 19,185
patients, the risk of intracranial hemorrhage with clopidogreland aspirin was 0.33% and 0.47%, respectively.10 In the MATCH
trial11 comparing dual antiplatelet arm to a single antiplatelet
agent among 7599 patients with a recent ischemic stroke and
high risk of vascular events, there was no difference in efﬁcacy
outcomes, but the risk of life-threatening bleeds was higher in
the clopidogrel and aspirin group [2.6%] vs. [1.3%]; absolute risk
increase was 1.3% [95% CI 0.6–1.9] in the clopidogrel group
alone.11 Primary intracranial hemorrhage occurred in 1% of the
patients in the clopidogrel and aspirin group as compared to
less than 1% in the clopidogrel group {% difference 0.40 (0.04–
0.76)}. Monotherapy thus remained a preferred treatment for
secondary stroke prevention. In a systematic review of RCT's
with mono versus dual antiplatelets among stroke patients,
the authors concluded a improved stroke recurrence with the
use of dual antiplatelets at the expense of a nonsigniﬁcant
trend for major bleeding complications, although the overall
events were small in number with wide conﬁdence intervals
(CIs).12 The recent CHANCE trial,13 conducted among patients
with ‘‘minor stroke’’ and TIA, compared efﬁcacy of aspirin and
clopidogrel given for ﬁrst 21 days versus aspirin alone in
reducing recurrence of stroke at 90 days. There was a
signiﬁcant reduction in stroke occurrence with no major
increase in any bleeding or intracerebral hemorrhage. An
updated meta-analysis, including the CHANCE trial, suggested
that early dual antiplatelet agents for a limited period reduce
risk of stroke recurrence (risk ratio, 0.69; 95% CI 0.60–0.80;
p < 0.001) with a nonsigniﬁcantly increased risk of major
bleeding (risk ratio, 1.35; 95% CI 0.70–2.59, p = 0.37).14 However,
two recent meta-analyses for long-term stroke prevention
suggest single agent as the preferred long-term stroke
prevention strategy in view of safety concerns for bleeding
events.15,16 Monotherapy thus remains a standard treatment
for long-term secondary stroke prevention.17
Among patients with acute coronary syndrome, however,
the standard practice is to treat with dual antiplatelet agents
for a year or even longer, especially following a stenting
procedure. In the CURE (Clopidogrel in Unstable Angina to
Prevent Recurrent Events) trial18 assessing addition of
clopidogrel with aspirin for unstable angina, although
major bleeding in the dual antiplatelet group was higher
(3.7% vs. 2.7%; relative risk, 1.38; p = 0.001), the episodes of
Table 1 – Intracranial bleeding rates in major ACS trials.
Trial Number of
patients
Group 1 Group 2 Intracranial
bleeding group 1
Intracranial
bleeding group 2
Hazard ration,
95% CI, p value
CURE 12,652 Clopidogrel Placebo No difference in
two group.
CLARITY–TIMI 3491 Clopidogrel Placebo 8 (0.5) 12 (0.7) 0.38
COMMIT 45,852 Clopidogrel Placebo Fatal cerebral
39 (0.17%)
Fatal cerebral
41 (0.18%)
Nonfatal cerebral Nonfatal cerebral
16 (0.07%) 15 (0 07%) Not signiﬁcant
CURRENT–OASIS 7 25,086 Double-dose
Clopidogrel
Higher dose
aspirin
Standard dose
clopidogrel
Low dose
aspirin
4 (0.03)
6 (0.05)
6 (0.05)
4 (0.03)
0.67 (0.19–2.37), p = 0.53
1.51 (0.42–5.33), p = 0.53
TRITON–TIMI 38 13,608 Prasugrel Clopidogrel 19 (0.3%) 17 (0.3%) 1.12 (0.58–2.15), p = 0.74
TRILOGY–ACS 9326 Prasugrel Clopidogrel 14 (0.3) 19 (0.4) 0.76 (0.38–1.51), p = 0.42
PLATO 18,624 Ticagrelor Clopidogrel 26(0.3) 14(0.8) 1.87 (0.98–3.58), p = 0.06
CHAMPION PCI 8877 Cangrelor Clopidogrel 1 (<0.1) 0 (0.0)
CHAMIPON
PLATFORM
5301 Cangrelor Placebo 2 (0.1) 1 (<0.1) 1.99 (0.18–21.98), p = 0.57
DAPT 9961 Clopidogrel Placebo 16 (0.34%) 13 (0.28%) 0.06% (0.17%, 0.28%)
p = 0.60
CURE: Clopidogrel in Unstable Angina to Prevent Recurrent Events trial. N Engl J Med 2001; 345: 494–502.
CLARITY–TIMI: Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY) – Thrombolysis in Myocardial Infarction (TIMI). N Engl J Med 2005;
352: 1179–89.
COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Lancet 2005; 366: 1607–21.
CURRENT–OASIS 7. Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events–Seventh Organization to Assess Strategies in
Ischemic Syndromes. N Engl J Med 2010; 363: 930–42.
TRITON–TIMI 38: Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel – Thrombolysis in
Myocardial Infarction. N Engl J Med 2007; 357: 2001–15.
TRILOGY–ACS: The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes.
PLATO: Study of Platelet Inhibition and Patient Outcomes (PLATO). N Engl J Med 2009; 361: 1045–57.
CHAMPION PCI: Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. N Engl J Med 2009; 361: 2318–29.
CHAMPION PLATFORM: Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition after PCI. N Engl J Med 2009;
361: 2330–41.
DAPT: Dual antiplatelet study. N Engl J Med 2014; 371: 2155–66.
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The rates of hemorrhagic stroke were similar (0.1%). In the
CLARITY–TIMI trial, patients between 18 and 75 years with ST-
segment elevation myocardial infarction (STEMI) were trea-
ted with clopidogrel or placebo plus aspirin with no signiﬁcant
differences in major or intracranial bleeding rates between
the two groups.19
Ticagrelor, a relatively newer agent, is a reversible allosteric
antagonist of ADP receptor of subtype P2Y12. In the pivotal
PLATO (platelet inhibition and patient outcome) trial,7
ticagrelor signiﬁcantly reduced the rate of primary composite
endpoint, compared with clopidogrel (9% vs. 10.7%, p = 0.0025).
This beneﬁt was observed both in the ﬁrst 30 days and the
remaining period of analysis.20 Also, rates of ﬁrst or recurrent
primary outcome events were in favor of ticagleror.21 In a
substudy of elderly patients in the PLATO trial, the authors did
not observe signiﬁcant differences in beneﬁts among patients
above or below 75 years of age and neither was there any
difference in PLATO-deﬁned major bleeding rates among
patients below 75 years (hazard ratio, 1.02; 95% CI 0.82–1.27)
versus those above 75 years (hazard ratio 1.04; 95% CI 0.94–
1.5).22 Ticagleror also reduced the relative risk of stent
thrombosis among the patients who received a stent during
the study by 38%.23 In a retrospective analysis of the PLATO
study, no signiﬁcant differences were found between the Asianversus the non-Asian populations with respect to efﬁcacy or
bleeding rates.24
Detailed bleeding rates have been analyzed in a post hoc
analysis of the PLATO trial.25 The rates of PLATO major
bleeding (11.6 vs. 11.2%; p = 0.43), TIMI major bleeding (7.9 vs.
7.7%, p = 0.56), GUSTO severe bleeding (2.9 vs. 3.1%, p = 0.22),
and procedure-related bleeding were similar among the two
groups. The occurrence of non-CABG major bleeding (4.5 vs.
3.8%, p = 0.02) and nonprocedure-related major bleeding (3.1
vs. 2.3%, p = 0.05) was more common in ticagrelor-treated
patients, mainly after 30 days on treatment. The rates of
intracranial bleeding were small, 26 (0.34%) in the ticagrelor
arm and 15 (0.19%) among clopidogrel-treated patients
( p = 0.08). 22 (0.26%) of the ticagrelor-treated patients and 13
(0.15%) of the clopidogrel-treated patients were reported to
have a hemorrhagic stroke ( p = 0.13). The fatal intracranial
events were however higher in ticagrelor arm, 11 (0.21%)
versus 2 (0.03%) in the clopidogrel arm ( p = 0.02). Apart from
the previous history of ICH, no speciﬁc risk factor for
intracranial bleeding could be identiﬁed. Interestingly, the
authors observed that the non-CABG or nonprocedure-related
major bleeding was more often after the initial 30 days. After
modeling for control of all baseline factors in the study, non-
CABG-related major bleeding did not differ among two groups
but higher non-CABG-related major or minor bleeding rates
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the initial 30 days (5.11 vs. 4.02%; HR 1.28; 95% CI 1.10–1.501;
p = 0.002) and after (3.98 vs. 2.97%; HR 1.35; 95% CI 1.09–1.67;
p = 0.006).
Based on observations from studies, some authors have
suggested that ticagleror should be avoided among patients
with ACS with a past history of ICH, hepatic impairment, high
bleeding risk, and concomitant use of anticoagulants.26 Risk
factors observed for bleeding during antiplatelet therapy are
advanced age (>75 years), female sex, use of NSAIDs, antic-
oagulants, or glycoprotein IIb/IIIa inhibitors, history of
bleeding, stroke, or transient ischemic attack.27 Clopidogrel
may be a preferred agent in place of newer oral antiplatelet
agents in patients with higher bleeding risk, need for
concomitant anticoagulation, stable PCI-treated patients,
and clear contraindications to either ticagleror or prasugrel.28
In a recent meta-analysis, including 12 RCT's, the authors
concluded that the new oral P2Y12 inhibitors reduce ischemic
events, ‘‘without any obvious increase in major bleeding in
patients with CAD’’, the effect being more favorable among
STEMI patients.2 However, important concerns have been
raised about the variability in deﬁnitions for bleeding among
ACS trials of antiplatelet agents, which seems to create a
marked variation of bleeding rates across trials.29 Authors
suggest that three factors, which most consistently determine
the bleeding risk, are deﬁnition, timing of bleeding assess-
ment, and rates of CABG surgery. Other factors inﬂuencing
bleeding rates include age, pharmacological and intervention-
al cointerventions, renal dysfunction, and type of ACS
presentation. A standardized reporting standard for bleeding
has been previously proposed.30
The optimum duration of therapy with dual antiplatelet
agents in ACS still remains unclear. Following coronary
stenting, evidence to treat longer than prescribed period
may be associated be higher risk of bleeding, as shown in the
recent results of ARCTIC-interruption trial31 with no beneﬁt in
ischemic or stent-related complications.32 A recent meta-
analysis on long-term dual antiplatelet therapy (>1 year)
following a drug-eluting stent suggests loss of net beneﬁt due
to increased bleeding-related noncardiovascular mortality.33 A
recent meta-analysis on the long-term use of dual antiplate-
lets in different cardiovascular disorders however does not
suggest any long-term mortality differences between the
aspirin alone or shorter and longer durations of dual
antiplatelet therapy.34 These variations among published
meta-analyses are likely due to differences in study inclusions
and methodology.35
This case highlights the known bleeding risks of dual
antiplatelet therapy, especially in the elderly who may have
comorbidities. As for secondary long-term stroke prevention,
single antiplatelet therapy is the standard of care apart from
situations like vascular stenting and intensive management of
intracranial vascular stenosis based on the results of SAMM-
PRIS trial.17,36 In cardiology practice, however, dual antiplatelet
therapy is an accepted standard of care for ACS patients and
even the threat of triple therapy is accepted in situations like
associated atrial ﬁbrillation or mechanical valves, where
evidence does point towards worrisome bleeding rates.37,38
Although there is some suggestion from the data that the
newer antiplatelet agents may have beneﬁt at the expense ofincrease in bleeding, reporting standards needs standardiza-
tion and no unbiased inferences can be drawn about safety of
one versus the other.
Till future guides us about individualized pharmacotherapy
and risks with a speciﬁc drug, caution, safety, and detailed
individual patient risk assessment proﬁle before selecting an
agent remain the key to safe outcomes.
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